Caldwell Sutter Capital’s Lipocine LPCN Stock Holding History

Caldwell Sutter Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21K	Hold	471	–	–	﹤0.01%	845
2026 Q1	$3.76K	Hold	471	–	–	﹤0.01%	681
2025 Q4	$3.78K	Hold	471	–	–	﹤0.01%	663
2025 Q3	$1.34K	Hold	471	–	–	﹤0.01%	776
2025 Q2	$1.49K	Hold	471	–	–	﹤0.01%	747
2025 Q1	$1.5K	Hold	471	–	–	﹤0.01%	760
2024 Q4	$2.3K	Hold	471	–	–	﹤0.01%	732
2024 Q3	$2.12K	Hold	471	–	–	﹤0.01%	749
2024 Q2	$3.88K	Hold	471	–	–	﹤0.01%	664
2024 Q1	$2.45K	Hold	471	–	–	﹤0.01%	730
2023 Q4	$1.31K	Hold	471	–	–	﹤0.01%	801
2023 Q3	$1.4K	Hold	471	–	–	﹤0.01%	767
2023 Q2	$2.37K	Hold	471	–	–	﹤0.01%	715
2023 Q1	$2.54K	Buy	+471	New	+$3.64K	﹤0.01%	477

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Caldwell Sutter Capital's LPCN Position: Q2 2026 in Review

Caldwell Sutter Capital held its Lipocine (LPCN) position steady in Q2 2026 at 471 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #845.

Caldwell Sutter Capital first reported a position in LPCN in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.88K in Q2 2024. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Caldwell Sutter Capital held 471 shares of Lipocine worth $1.21K as of Q2 2026.
Caldwell Sutter Capital left its Lipocine share count unchanged in Q2 2026.
Lipocine made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #845 holding.
Caldwell Sutter Capital first reported a position in Lipocine in Q1 2023 and has held it in 14 quarters since.
Caldwell Sutter Capital's Lipocine position peaked at $3.88K in Q2 2024.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.